Univar is now exclusively distributing Dow's Carbowax Sentry PEGs in Europe and the range is proving popular at CPhI 2010 with manufacturers facing restricted supply from other sources.
Invida has acquired a stake in Indonesia-based MUGI, giving it the local manufacturing presence needed to offer partners access to “a vast untapped market”.
A 38 per cent increase in revenues helped PDI cut its operating loss to $1.7m (€1.3m) in the first quarter, furthering the contract sales provider’s goal of achieving profitability by the end of the year.
Cambrex has posted a 55 per cent drop in operating profit in the first quarter, underpinned by the timing of orders, disruption to a customer’s supply chain and lower pricing of certain generic APIs.
Synthon has completed the acquisition of Mexico-based Nafar Laboratories, adding to its presence in Latin America which includes recent purchases in Chile and Argentina.
inVentiv Health has rolled-out FlightPath, a new bespoke service designed to help pharmaceutical and biotechnology companies chart a clear course to commercial launch.
West Pharmaceutical Services is laying off 100 staff as part of restructuring efforts after its third quarter results fell short of expectations, despite operating profit increasing by 45 per cent.
Symphony Metro Pharma Solutions and HP Solutions have created a new application that, they claim, can help drug marketeers identify activities with the greatest revenue potential.
LGC Standards has made the “next logical step” in its “concerted effort” to expand internationally by opening an office in St Petersburg, Russia, less than six months after it moved into China.
United Drug’s contract packaging business is expected to report a significant dip in profits but strong performance in the sales division helped push up its share price.
Millipore hopes its $23m (€18m) swoop for Guava Technologies will draw attention away from the underperformance of its bioprocess division, revenue from which fell 6 per cent in Q4 to $214m (€165m) and 2 per cent for 2008 overall.
Teva has made a big push into the biosimilars market through a joint venture with Lonza, which will give the generics giant expertise in biologics manufacture.
The sales growth of generic drugs slowed considerably in 2008, dipping below the customary double digits to 3.6 per cent, according to a report by IMS Health.
inVentive Health has been contracted to provide marketing and branding services for fellow US based generic injectables developer GeneraMedix, specifically focusing on the latter’s epoprostenol hypertension treatment.
Cambrex joined a number of its peers in the contract services sector by reporting pressure on third quarter sales and earnings, providing further evidence that outsourcing companies are not immune to the economic downturn.
US drugmaker Par Pharmaceuticals is wielding the axe at its generics division, cutting 190 jobs and refocusing its R&D efforts on the completion of its current roster of product candidates
Japan’s Shionogi is paying $1.4bn (€959m) for US drugmaker Sciele Pharma as part of a plan to strengthen its sales position in the country’s $286bn a year drug market.
Gerresheimer has formally started the process to sell off its technical plastics business, keeping its promise to exit non-core businesses and focus on more lucrative sectors such as medical and pharmaceutical plastics.
Catalent Pharma Solutions has reported a profit drop in its latest
financial results, completed the sale of one of its businesses, and
is undergoing regulatory scrutiny over the overall control and
management of quality systems at...
Australian firm Fluorotechnics wants to bolster the sales of its
proteomics products in Japan and so has signed up Osaka firm Wako
Pure Chemical Industries to help.
After losing a key Novartis contract and getting caught up in the
Inyx collapse, Inventiv Health had good news this week when it
reported its third quarter results.
Japanese pharma firm Takeda beat off strong competition from the
likes of Coca-Cola to take home the dubious honour of Consumer
International's 'Worst Product' award thanks to its sleeping pill
ad.
Relaunching pharmaceutical products in a bid to preserve an earlier
product's existing market share and maintain revenues is a common
tactic in the pharma industry, but, as a recent report notes,
kicking off development plans...
Agilent Technologies has signed an agreement with Groton Biosystems
to co-market measuring solutions for the pharmaceutical industry,
as the Process Analytical Technology (PAT) initiative gains
popularity among drug manufacturers...
The contract sales and marketing business will reach $5.2bn (€4bn)
by 2011, as it represents an ideal outsourcing opportunity for
pharma companies competing in this fast growing sector, according
to new market research.
Companies in the healthcare sector, including drug discovery
technologies, healthcare and life sciences IT, and medical devices
were out in force this week at Frost & Sullivan's 2006
Excellence in Healthcare Awards
Pharmaceutical wholesalers in Europe need to evolve to meet the
changing pharma market and a world of opportunity awaits for those
willing to think beyond their traditional business model and move
to compete in the outsourcing arena.
Troubled contract sales and marketing firm PDI has recently won a
much-needed new sales contract and made two new top executive
appointments as part of ongoing efforts to turn its flagging
business around.
Cardinal Health has implemented a series of business reshuffles and
cost cutting measures in the hope of pulling itself out of poor
profitability after disappointing third quarter results.
Celesio has bought a 30 per cent stake in Pharmexx, the number two
contract sales organisation in Europe, in a bid to get a foothold
in this market segment and diversify its business.
The European Association of Pharmaceutical Full-line Wholesalers
(GIRP) has outlined measures it is taking to keep counterfeit
medicines out of the legitimate supply chain while urging
pharmaceutical manufacturers and pharmacists...
Ventiv Health has spent the last month buying up companies. After
buying Aheris in February, the company has since agreed to acquire
US clinical services provider Synergos, as well as Canadian
healthcare marketing and communications...
Rising prices globally have helped Dutch chemicals manufacturer DSM
go back to profit in Q4, up to €112m (€134m) from €3m in the red a
year ago, with operating profits in its Life Science division
almost doubling to €39m, albeit thanks...
Porter Novelli, one of the world's leading public relations
agencies, has acquired Californian life sciences agency, Atkins +
Associates, in a move to establish a new business unit that will
serve as the first corporate and marketing...
PDI, who provides sales and marketing services to the
pharmaceutical industry, have received a new sales representative
contract in the US from GlaxoSmithKline (GSK), worth $65-70m
(€55-59m).
Ventiv health reported a strong performance across all its business
units in the third quarter, with total revenues increasing by 44
per cent to $128.4 million (€107.6 million) compared to the third
quarter of 2004.
The consolidation in the generic pharmaceutical industry continues
apace, with companies in the easterly reaches of Europe now getting
in on the act. Czech Republic-headquartered Zentiva has signed an
agreement to acquire 51 per cent...
Separations specialist Whatman is starting to reap the benefits of
its acquisition of Schleicher & Schuell, but had a difficult
first half to the year with the group's combined revenues down
marginally compared to first-half...
